Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Immunome, Inc.NASDAQ: IMNM
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization growth accelerates
Q3 FY2026 depreciation & amortization of $1.07M rose 45.3% year over year, ahead of the +35.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 8.3% from the prior quarter. Over 3 fiscal years it compounded at +67.3% a year.
Context
- Depreciation & amortization amounted to 42.6% of revenue in FY2025, up 19.3 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +45.3% holds above the trailing-twelve-month pace of +35.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 2.96M USD
- Year-over-year change
- +40.6%
- 4-year CAGR
- +40.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.96M | +40.6% |
| FY2024 | 2024-12-31 | 2.1M | +188.7% |
| FY2023 | 2023-12-31 | 728K | +15.4% |
| FY2022 | 2022-12-31 | 631K | -16.4% |
| FY2021 | 2021-12-31 | 755K | — |
Depreciation & Amortization vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +35.4% is the 2nd highest of 10, against a peer median of -7.1%.
- Over three fiscal years its annual growth of +67.3% compares with a peer median of +7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | €12.05M EUR | -2.4% | +19.6% | 32.3% | |
| LTM Mar 2026 | $6.94M USD | -7.1% | -22.5% | 4.4% | |
| LTM Mar 2026 | $6.7M USD | -8.9% | +8.8% | 6.7% | |
| LTM Sep 2026 | $3.76M USD | +35.4% | +67.3% | — | |
| LTM Sep 2026 | $3.73M USD | +10.4% | +5.3% | 3333.9% | |
| LTM Mar 2026 | $3.59M USD | — | — | — | |
| LTM Mar 2026 | $3.36M USD | -17.0% | -23.1% | 0.9% | |
| LTM Mar 2026 | $511.27K USD | -107.2% | +20.3% | 0.8% | |
| LTM Mar 2026 | $436.09K USD | +189.3% | +454.8% | — | |
| LTM Sep 2026 | $152K USD | -97.9% | — | — | |
| LTM Mar 2026 | $112K USD | +33.3% | -34.1% | — | |
| Peer median (excluding IMNM) | — | -7.1% | +7.0% | 5.6% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| Deferred Income Tax | (500K) | (7.27M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.45M | 5.33M | 6.22M | 15.75M | 25.69M |
| Change in Working Capital | 2.78M | 2.24M | 12M | 14.87M | (15.23M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.78M | (677K) | (608K) | 9.53M | (9.16M) |
| Other Working Capital | 998K | 2.92M | 12.61M | 5.35M | (6.06M) |
| Other Non-Cash Items | 4K | 7.27M | 80.29M | 149.45M | 8.06M |
| Operating Cash Flow | (18.23M) | (28.69M) | (7.57M) | (110.79M) | (190.92M) |
| Capital Expenditures | (79K) | (248K) | (831K) | (53.51M) | (9.69M) |
| Acquisitions (Net) | 0 | 0 | 9.28M | 0 | 0 |
| Purchases of Investments | 0 | 0 | (38.93M) | (186.56M) | (123.27M) |
| Sales of Investments | 0 | 0 | 0 | 155M | 200M |
| Other Investing Activities | 0 | 0 | 0 | (46.34M) | (6.25M) |
| Investing Cash Flow | (79K) | (248K) | (30.48M) | (85.06M) | 60.8M |
| Debt Repayment | (113K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 27.23M | 32K | 34K | 250M | 640.36M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 656K | 0 | 116.37M | (9.47M) | 0 |
| Financing Cash Flow | 27.77M | 32K | 116.41M | 240.53M | 640.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.46M | (28.91M) | 78.36M | 44.67M | 510.24M |
| Free Cash Flow | (18.31M) | (28.94M) | (8.4M) | (164.3M) | (200.6M) |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.